Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Pharmakologie (14 Abbildungen)
Übersicht


Zum ersten Bild Abb. 1: Pharmakologie Abb. 2: Angiotensin-II-Antagonisten Abb. 3: Telmisartan - Röntgenstruktur Aktuelles Bild - Abb. 4: Angiotensin-I-Rezeptor Abb. 5: Plasma-Halbwertzeit Abb. 6: Angiotensin-I-Rezeptorblocker - Verteilungsvolumina Abb. 7: Telmisartan - PPAR-Gamma Zum letzten Bild
Abbildung 4: Angiotensin-I-Rezeptor
In vivo studies show that telmisartan is a potent and long-acting antagonist of the hypertensive effects of exogenously administered angiotensin II. In the rabbit aorta, the maximal contractile response to angiotensin II was dose-dependently decreased by 40% to 50% across a dose range of 10 to 1000 nM. No agonist activity was detected at any concentration.1 Even high concentrations of angiotensin II were unable to overcome the receptor blockade, demonstrating that telmisartan manifests an insurmountable AT1 receptor antagonism. 1. Wienen W, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245–252.
 
Angiotensin-I-Rezeptor
Vorheriges Bild Nächstes Bild   


Abbildung 4: Angiotensin-I-Rezeptor
In vivo studies show that telmisartan is a potent and long-acting antagonist of the hypertensive effects of exogenously administered angiotensin II. In the rabbit aorta, the maximal contractile response to angiotensin II was dose-dependently decreased by 40% to 50% across a dose range of 10 to 1000 nM. No agonist activity was detected at any concentration.1 Even high concentrations of angiotensin II were unable to overcome the receptor blockade, demonstrating that telmisartan manifests an insurmountable AT1 receptor antagonism. 1. Wienen W, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110: 245–252.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung